User profiles for "author:Fabrizio Bossa"
 | Fabrizio BossaDirigente Medico - Fondazione Casa Sollievo della Sofferenza - IRCCS - San Giovanni … Verified email at operapadrepio.it Cited by 7383 |
Ulcerative colitis–risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study
Ulcerative colitis is a chronic inflammatory disease of the colon that presents as diarrhea
and gastrointestinal bleeding. We performed a genome-wide association study using DNA …
and gastrointestinal bleeding. We performed a genome-wide association study using DNA …
[HTML][HTML] Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
G Monteleone, MF Neurath, S Ardizzone… - … England Journal of …, 2015 - Mass Medical Soc
Background Crohn's disease–related inflammation is characterized by reduced activity of
the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels …
the immunosuppressive cytokine transforming growth factor β1 (TGF-β1) due to high levels …
Advanced age is an independent risk factor for severe infections and mortality in patients given anti–tumor necrosis factor therapy for inflammatory bowel disease
BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients
more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and …
more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and …
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study
C Bezzio, S Saibeni, A Variola, M Allocca, A Massari… - Gut, 2020 - gut.bmj.com
Objectives COVID-19 has rapidly become a major health emergency worldwide. Patients
with IBD are at increased risk of infection, especially when they have active disease and are …
with IBD are at increased risk of infection, especially when they have active disease and are …
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy
MF Chiappetta, A Viola, M Mastronardi… - Expert Opinion on …, 2021 - Taylor & Francis
Background Efficacy and safety of ustekinumab for the treatment of ulcerative colitis (UC)
has been demonstrated in clinical trials, but few real-world data are available so far. The aim …
has been demonstrated in clinical trials, but few real-world data are available so far. The aim …
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
The first infliximab biosimilar for the treatment of inflammatory bowel disease (IBD) was
introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five …
introduced in 2013, and today eight anti-TNF alpha biosimilars (three for infliximab and five …
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis …
BD Juran, GM Hirschfield, P Invernizzi… - Human molecular …, 2012 - academic.oup.com
To further characterize the genetic basis of primary biliary cirrhosis (PBC), we genotyped
2426 PBC patients and 5731 unaffected controls from three independent cohorts using a …
2426 PBC patients and 5731 unaffected controls from three independent cohorts using a …
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 …
S Danese, JF Colombel, M Lukas… - The lancet …, 2022 - thelancet.com
Background Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
previous phase 2 induction study, etrolizumab significantly improved clinical remission …
The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar
Background Few data are available on the safety and efficacy of infliximab biosimilar CT-
P13 in patients with ulcerative colitis and Crohn's disease. Methods A prospective …
P13 in patients with ulcerative colitis and Crohn's disease. Methods A prospective …
Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection
BACKGROUND & AIMS: Management of Clostridium difficile infection in patients with flaring
inflammatory bowel disease (IBD) has not been optimized. We investigated the effects of …
inflammatory bowel disease (IBD) has not been optimized. We investigated the effects of …